SCHEMBL18231641

SCHEMBL18231641

COC(=O)N1CC(C)C(I)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNB2 P17787 2/20 0.48
▸ CHRNA4 P43681 2/20 0.48
▸ CHRNB4 P30926 1/20 0.48
▸ CHRNA3 P32297 1/20 0.48
▸ TSHR P16473 1/20 0.45
▸ PDE4A P27815 1/20 0.37
▸ PDE4B Q07343 1/20 0.37
▸ PDE4C Q08493 1/20 0.37
▸ PDE4D Q08499 1/20 0.37
▸ EPHX1 P07099 1/20 0.33
▸ DPP4 P27487 1/20 0.32
▸ DPP8 Q6V1X1 1/20 0.32
▸ DPP9 Q86TI2 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ USP2 O75604 1/20 0.31
▸ NR1H2 P55055 1/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ BRD4 O60885 1/20 0.31
▸ CYP2D6 P10635 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16472382 0.85 CHRNB2 (0.57) CHRNB2CHRNA4CHRNB4CHRNA3TSHR
SCHEMBL12683426 0.85 CHRNB2 (0.57) CHRNB2CHRNA4CHRNB4CHRNA3TSHR
SCHEMBL18484867 0.79 — —
SCHEMBL10005081 0.76 — —
SCHEMBL16478760 0.74 CHRNB2 (0.47) CHRNB2CHRNA4CHRNB4CHRNA3TSHR
SCHEMBL12683361 0.74 CHRNB2 (0.47) CHRNB2CHRNA4CHRNB4CHRNA3TSHR
SCHEMBL18498089 0.73 CHRNB2 (0.72) CHRNB2CHRNA4CHRNB4CHRNA3TSHR
SCHEMBL16472256 0.73 CHRNB2 (0.46) CHRNB2CHRNA4CHRNB4CHRNA3TSHR
SCHEMBL16472314 0.73 CHRNB2 (0.46) CHRNB2CHRNA4CHRNB4CHRNA3TSHR
SCHEMBL14752967 0.72 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2686321-B1 PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES BRISTOL MYERS SQUIBB CO (US) 2016-11-16 — — EP disclosed
Send feedback